Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases
Investigative Ophthalmology & Visual Science · 22.08.2024 · 65 (10) · 31
DOI: 10.1167/iovs.65.10.31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 22.08.2024. Verfasst von Kelleigh Hogan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Visual and Neurocognitive Rehabilitation Atlanta VA Medical Center Atlanta, GA, United States. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Age of Onset, Postmenopause, Estrogen Replacement Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: RRD VA.
Abstract (Originalsprache)
Purpose
Hormonal therapy (HT) has been suggested to lower the risk of developing glaucoma. Our goal was to investigate the association between HT use and the onset of glaucoma diagnosis in postmenopausal women.
Methods
This retrospective case-only study included female veterans with open-angle glaucoma from VA records between 2000 to 2019. Propensity score matching was used to match HT (n = 1926) users to untreated (n = 1026) women on multiple covariates (e.g., age of menopause, BMI, blood pressure, antihypertensive medications, and a co-morbidity index). A simple linear regression was used to evaluate the impact of HT duration on the age of glaucoma diagnosis, and multivariate linear regression analysis was used to determine which factors contributed to the age at diagnosis of glaucoma.
Results
We found a linear relationship between the age at diagnosis of glaucoma and menopause in women with (r = 0.54) and without HT (r = 0.57) use. HT users tended to have a later diagnosis of glaucoma. Our multivariate analysis found that 0-2 years, 2-5 years, and >5 years of HT use were associated with a 2.20 [confidence interval (CI), 1.64, 2.76], 3.74 [CI, 3.02, 4.46], and 4.51 [CI, 3.84, 5.18] years later diagnosis of glaucoma. An interaction (-0.009 [-0.015, -0.003]) was observed between HT duration and age of menopause diagnosis, with the impact of HT decreasing for later menopause ages.
Conclusions
Longer duration of HT use was associated with a later diagnosis of glaucoma in postmenopausal women in this case-only analysis. The impact of HT may be modulated by menopausal age, although further study is needed. The findings support a protective role of estrogen in glaucoma pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Visual and Neurocognitive Rehabilitation Atlanta VA Medical Center Atlanta, GA, United States.
- Department of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta GA, United States.
- Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States.
- Department of Biostatistics and Bioinformatics, Emory University School of Public Health, Atlanta, GA, United States.
- Technology-Based Eye Care Services Section, Regional Telehealth Services, VISN 7, Atlanta Veteran Affairs Health Care System, Atlanta, GA, United States.
Förderung
- RRD VA
Zitieren
APA
Hogan, K., Cui, X., Giangiacomo, A., & Feola, A. J. (2024). Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases. Investigative Ophthalmology & Visual Science, 65(10), 31. https://doi.org/10.1167/iovs.65.10.31
Vancouver
Hogan K, Cui X, Giangiacomo A, Feola AJ. Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases. Investigative Ophthalmology & Visual Science. 2024;65(10):31. doi:10.1167/iovs.65.10.31
BibTeX
@article{Hogan2024,
author = {Hogan, Kelleigh and Cui, Xiangqin and Giangiacomo, Annette and Feola, Andrew J},
title = {Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
volume = {65},
number = {10},
pages = {31},
doi = {10.1167/iovs.65.10.31}
}
EUVIMED